JP2022550816A5 - - Google Patents
Info
- Publication number
- JP2022550816A5 JP2022550816A5 JP2022520223A JP2022520223A JP2022550816A5 JP 2022550816 A5 JP2022550816 A5 JP 2022550816A5 JP 2022520223 A JP2022520223 A JP 2022520223A JP 2022520223 A JP2022520223 A JP 2022520223A JP 2022550816 A5 JP2022550816 A5 JP 2022550816A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- antibody according
- seq
- conjugated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025066906A JP7864224B2 (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910988P | 2019-10-04 | 2019-10-04 | |
| US62/910,988 | 2019-10-04 | ||
| PCT/US2020/054037 WO2021067776A2 (en) | 2019-10-04 | 2020-10-02 | Anti-pd-l1 antibodies and antibody-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066906A Division JP7864224B2 (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550816A JP2022550816A (ja) | 2022-12-05 |
| JP2022550816A5 true JP2022550816A5 (enExample) | 2023-08-07 |
| JP7668791B2 JP7668791B2 (ja) | 2025-04-25 |
Family
ID=72964849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520223A Active JP7668791B2 (ja) | 2019-10-04 | 2020-10-02 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
| JP2025066906A Active JP7864224B2 (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066906A Active JP7864224B2 (ja) | 2019-10-04 | 2025-04-15 | 抗ｐｄ－ｌ１抗体および抗体－薬物コンジュゲート |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12421312B2 (enExample) |
| EP (1) | EP4038101A2 (enExample) |
| JP (2) | JP7668791B2 (enExample) |
| KR (1) | KR102995917B1 (enExample) |
| CN (3) | CN122103344A (enExample) |
| AR (1) | AR120147A1 (enExample) |
| AU (1) | AU2020358859A1 (enExample) |
| BR (1) | BR112022005114A2 (enExample) |
| CA (1) | CA3155634A1 (enExample) |
| IL (1) | IL291541A (enExample) |
| MX (1) | MX2022003517A (enExample) |
| TW (1) | TWI883057B (enExample) |
| WO (1) | WO2021067776A2 (enExample) |
| ZA (1) | ZA202204437B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| CN111655295B (zh) | 2018-08-29 | 2024-05-28 | 荣昌生物制药(烟台)股份有限公司 | 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| EP4331616A4 (en) * | 2021-05-13 | 2026-03-18 | Univ Tsinghua | ANTIBODY-DRUG CONJUGATE, RELATED PREPARATION PROCESS AND ASSOCIATED USE |
| TW202306588A (zh) * | 2021-05-21 | 2023-02-16 | 中國大陸商榮昌生物製藥（煙臺）股份有限公司 | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 |
| WO2023126821A1 (en) * | 2021-12-29 | 2023-07-06 | Curateq Biologics Private Limited | C1q binding assay |
| AU2022435471A1 (en) * | 2022-01-18 | 2024-05-30 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| US20250171542A1 (en) * | 2022-02-28 | 2025-05-29 | Adept Therapeutics Inc. | Anti-programmed death-ligand 1 (pd-l1) antibodies |
| WO2023217227A1 (zh) * | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| IL318450A (en) * | 2022-08-03 | 2025-03-01 | Seagen Inc | Immunostimulatory ANTI-PD-L1-Drug conjugates |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| WO2024211236A2 (en) * | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| KR20260007619A (ko) | 2023-05-09 | 2026-01-14 | 상하이 헨리우스 바이오테크, 인크. | 항-pdl1 항체-약물 접합체 및 응용 |
| WO2024245380A1 (en) | 2023-05-31 | 2024-12-05 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| EP4754149A1 (en) * | 2023-07-29 | 2026-06-10 | Shanghai Kaijin Biotechnology , Ltd | Modified type e multi-specific antibodies |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EP0871490B1 (en) | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| KR20170128256A (ko) | 2015-03-18 | 2017-11-22 | 시애틀 지네틱스, 인크. | Cd48 항체 및 이의 접합체 |
| EP3432924A1 (en) * | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN109195991B (zh) | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | 对糖基化pd-l1特异的双重功能抗体及其使用方法 |
| US11135307B2 (en) * | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| CN110621787A (zh) | 2017-04-14 | 2019-12-27 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| US12655186B2 (en) * | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CN111936169A (zh) | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
-
2020
- 2020-10-02 BR BR112022005114A patent/BR112022005114A2/pt unknown
- 2020-10-02 KR KR1020227012974A patent/KR102995917B1/ko active Active
- 2020-10-02 US US17/061,998 patent/US12421312B2/en active Active
- 2020-10-02 AR ARP200102743A patent/AR120147A1/es unknown
- 2020-10-02 CN CN202610277062.XA patent/CN122103344A/zh active Pending
- 2020-10-02 EP EP20793914.1A patent/EP4038101A2/en active Pending
- 2020-10-02 CN CN202080082113.4A patent/CN115151564B/zh active Active
- 2020-10-02 WO PCT/US2020/054037 patent/WO2021067776A2/en not_active Ceased
- 2020-10-02 AU AU2020358859A patent/AU2020358859A1/en active Pending
- 2020-10-02 JP JP2022520223A patent/JP7668791B2/ja active Active
- 2020-10-02 MX MX2022003517A patent/MX2022003517A/es unknown
- 2020-10-02 CA CA3155634A patent/CA3155634A1/en active Pending
- 2020-10-02 CN CN202610277034.8A patent/CN122255273A/zh active Pending
- 2020-10-05 TW TW109134497A patent/TWI883057B/zh active
-
2022
- 2022-03-21 IL IL291541A patent/IL291541A/en unknown
- 2022-04-20 ZA ZA2022/04437A patent/ZA202204437B/en unknown
-
2025
- 2025-04-15 JP JP2025066906A patent/JP7864224B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110240655B (zh) | 抗her2抗体及其缀合物 | |
| AU2012235817B2 (en) | Antibody-drug conjugates | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| US12441795B2 (en) | Anti-ROR1 antibodies and preparation method and uses thereof | |
| JP2021102648A (ja) | 抗ｆｏｌｒ１免疫複合体投与計画 | |
| US11000598B2 (en) | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | |
| JP2022506072A5 (enExample) | ||
| CN107406497A (zh) | 半胱氨酸连接的纳米抗体二聚体 | |
| WO2023102875A1 (en) | Anti-cdh6 antibody drug conjugate | |
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| JP7455188B2 (ja) | コンジュゲーションのためのポリペプチド複合体及びその応用 | |
| TW202540197A (zh) | 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症 | |
| WO2018232164A1 (en) | Antibody drug conjugates that bind lgr5 | |
| US20260021194A1 (en) | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload | |
| JP2026505934A (ja) | Ｔｒｏｐ２結合剤およびそのコンジュゲート | |
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| JP2026512687A (ja) | ヒト化ｌ１ｃａｍ抗体－薬物複合体 | |
| JP2024540536A5 (enExample) | ||
| TW201922796A (zh) | 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑 | |
| JP2025521609A (ja) | 抗体可変領域の変異体及びその使用 | |
| CN121319203A (zh) | 双特异性抗体和免疫偶联物及其用途 | |
| TW202305008A (zh) | 三特異性抗體、其製備方法和用途 | |
| CN120173126A (zh) | 一种融合蛋白、包括其的adc及其应用 | |
| CN115991775A (zh) | 抗cxcr4单域抗体、双特异性抗体及药物偶联物 |